Teriflunomide (Aubagio) holds a license for adult RRMS with an efficacy of roughly 30% relapse rate reduction versus placebo (dummy tablet). The long awaited study in paediatric MS (TERIKIDS study) recently published, however has failed to meet its primary endpoint ֠time to first confirmed clinical relapse in the teriflunomide group vs. placebo. The probability [ŝ